To investigate the clinical efficacy of cinobufotalin capsule combined CAF in the treatment of moderate and advanced breast cancer.Methods:A total of 41 patients with moderate and advanced breast cancer who were admitted and treated in our hospital from February 2015 to February 2017 were selected and randomly divided into the combined group (20 cases) and CAF chemotherapy group (21 cases).The combined group was treated with cinobufotalin combined with CAF，and the CAF chemotherapy group received chemotherapy only.After 3 months' treatment，the short-term and long-term curative effects，quality of life，pain relief rate and adverse reactions were evaluated and compared between the two groups.Results:After 3 months' treatment，the effective rate (75.00%) in combined group was significantly higher than 52.38% in CAF chemotherapy group (P<0.05).The mean survival time of the combined group was 12 months，and the CAF chemotherapy group was 11 months.The difference between two groups was not statistically significant (P>0.05).The improvement rate of life quality in the combined group (45.00%) was significantly higher than that in the CAF chemotherapy group (23.81%) (P<0.05).Myelosuppression，alopecia，and gastrointestinal reactions were the major adverse events in both groups and the incidence of gastrointestinal reaction in the combined group (10%) was significantly lower than that in the CAF chemotherapy group (23.81%) (P<0.05).The incidence of alopecia in the combined group (20.00%) was significantly lower than that in the CAF chemotherapy group (38.10%) (P<0.05).After treatment，the improvement rate of pain in the combined group (65.00%) was better than that in the CAF chemotherapy group (52.81%) (P<0.05).Conclusion:Cinobufotalin combined chemotherapy with CAF has better short-term therapeutic effect on moderate and advanced breast cancer，and can relieve pain and improve the quality of life of patients with few side effects.